These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 2152594

  • 1. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment.
    Overgaard K, Hansen MA, Nielsen VA, Riis BJ, Christiansen C.
    Am J Med; 1990 Jul; 89(1):1-6. PubMed ID: 2152594
    [Abstract] [Full Text] [Related]

  • 2. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 3. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
    Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A.
    Bone; 1995 Oct; 17(4):383-90. PubMed ID: 8573412
    [Abstract] [Full Text] [Related]

  • 4. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F, Colak O, Armagan O, Alatas O, Oner C.
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [Abstract] [Full Text] [Related]

  • 5. Nasal calcitonin for treatment of established osteoporosis.
    Overgaard K, Riis BJ, Christiansen C, Pødenphant J, Johansen JS.
    Clin Endocrinol (Oxf); 1989 Apr; 30(4):435-42. PubMed ID: 2688995
    [Abstract] [Full Text] [Related]

  • 6. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
    Ofluoglu D, Karadag-Saygi E, Canbulat C, Gunduz OH, Kul-Panza E, Akyuz G.
    Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
    [Abstract] [Full Text] [Related]

  • 7. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
    Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, de Longueville M, Franchimont P.
    Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
    [Abstract] [Full Text] [Related]

  • 8. Rectal salmon calcitonin for the treatment of postmenopausal osteoporosis.
    Overgaard K, Hansen MA, Dirksen KL, Christiansen C.
    Calcif Tissue Int; 1992 Sep; 51(3):184-8. PubMed ID: 1422962
    [Abstract] [Full Text] [Related]

  • 9. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.
    Nielsen NM, von der Recke P, Hansen MA, Overgaard K, Christiansen C.
    Calcif Tissue Int; 1994 Jul; 55(1):8-11. PubMed ID: 7922794
    [Abstract] [Full Text] [Related]

  • 10. Preventive treatment of cortical bone loss with salmon nasal calcitonin in early postmenopausal women.
    Mango D, Ricci S, Manna P, Natili G, Dell'Acqua S.
    Minerva Endocrinol; 1993 Sep; 18(3):115-21. PubMed ID: 8183178
    [Abstract] [Full Text] [Related]

  • 11. Long-term treatment of established osteoporosis with intranasal calcitonin.
    Overgaard K, Christiansen C.
    Calcif Tissue Int; 1991 Sep; 49 Suppl():S60-3. PubMed ID: 1933601
    [Abstract] [Full Text] [Related]

  • 12. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
    Downs RW, Bell NH, Ettinger MP, Walsh BW, Favus MJ, Mako B, Wang L, Smith ME, Gormley GJ, Melton ME.
    J Clin Endocrinol Metab; 2000 May; 85(5):1783-8. PubMed ID: 10843152
    [Abstract] [Full Text] [Related]

  • 13. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.
    Overgaard K.
    Calcif Tissue Int; 1994 Aug; 55(2):82-6. PubMed ID: 7953984
    [Abstract] [Full Text] [Related]

  • 14. Treatment of postmenopausal osteoporosis with salmon calcitonin nasal spray: evaluation by bone mineral content and biochemical patterns.
    Tolino A, Romano L, Ronsini S, Riccio S, Montemagno U.
    Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):358-60. PubMed ID: 8370634
    [Abstract] [Full Text] [Related]

  • 15. [Effect of low calcitonin doses on bone remodeling in postmenopausal women with high bone turnover rate].
    Campusano C, López JM, Campino C, Cárdenas I, Rojas A.
    Rev Med Chil; 2000 Apr; 128(4):387-91. PubMed ID: 10962855
    [Abstract] [Full Text] [Related]

  • 16. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
    Ellerington MC, Hillard TC, Whitcroft SI, Marsh MS, Lees B, Banks LM, Whitehead MI, Stevenson JC.
    Calcif Tissue Int; 1996 Jul; 59(1):6-11. PubMed ID: 8661976
    [Abstract] [Full Text] [Related]

  • 17. Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study.
    Gonnelli S, Cepollaro C, Montomoli M, Gennari L, Montagnani A, Palmieri R, Gennari C.
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):55-61. PubMed ID: 9059558
    [Abstract] [Full Text] [Related]

  • 18. Effect of salmon calcitonin nasal spray on bone mass in patients with high turnover osteoporosis.
    Gennari C, Agnusdei D, Camporeale A.
    Osteoporos Int; 1993 Jan; 3 Suppl 1():208-10. PubMed ID: 8461563
    [No Abstract] [Full Text] [Related]

  • 19. The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis.
    Colpan L, Gur A, Cevik R, Nas K, Sarac AJ.
    Maturitas; 2005 Jul 16; 51(3):246-53. PubMed ID: 15978968
    [Abstract] [Full Text] [Related]

  • 20. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.
    Flicker L, Hopper JL, Larkins RG, Lichtenstein M, Buirski G, Wark JD.
    Osteoporos Int; 1997 Jul 16; 7(1):29-35. PubMed ID: 9102059
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.